Market Closed -
Hong Kong S.E.
04:08:22 2024-05-10 am EDT
|
5-day change
|
1st Jan Change
|
14.58
HKD
|
-2.15%
|
|
-1.09%
|
-51.24%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5,044
|
5,044
|
-
|
Enterprise Value (EV)
1 |
9,872
|
4,551
|
4,498
|
P/E ratio
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
26,343
x
|
8,572
x
|
6,770
x
|
EV / Revenue
|
25,574
x
|
7,732
x
|
6,036
x
|
EV / EBITDA
|
-27.5
x
|
-12
x
|
-9.35
x
|
EV / FCF
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
Price to Book
|
13.6
x
|
13.1
x
|
-49.9
x
|
Nbr of stocks (in thousands)
|
374,158
|
374,158
|
-
|
Reference price
2 |
13.48
|
13.48
|
13.48
|
Announcement Date
|
3/25/24
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.386
|
0.5885
|
0.7451
|
EBITDA
1 |
-359.6
|
-379.4
|
-480.8
|
EBIT
1 |
-372
|
-390.4
|
-490.4
|
Operating Margin
|
-96,368.39%
|
-66,337.79%
|
-65,820.02%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
Announcement Date
|
3/25/24
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
Net Cash position
1 |
297
|
494
|
547
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-49.7%
|
-67.2%
|
-845%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.000
|
1.030
|
-0.2700
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
Announcement Date
|
3/25/24
|
-
|
-
|
Last Close Price
13.48
CNY Average target price
15.13
CNY Spread / Average Target +12.24% Consensus |
1st Jan change
|
Capi.
|
---|
| -51.24% | 698M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|